Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Tropolones and Thailandepsin B as Lead-like Natural Compounds in the Development of Potent and Selective Histone Deacetylase Inhibitors

Author(s): Dilipkumar Pal* and Padum Lal

Volume 24, Issue 9, 2023

Published on: 11 July, 2023

Page: [698 - 717] Pages: 20

DOI: 10.2174/1389450124666230707144251

Price: $65

Abstract

Background: Tropolone and thailandepsin B are naturally occurring substances that are primarily isolated from fungi and plants, although they can also be found in certain bacteria. Tropolones belong to an important class of aromatic compounds with a seven-membered nonbenzenoid ring structure. Thailandepsins are a group of natural products that were initially discovered in the culture broth of the Gram-negative bacterium Burkholderia thailandensis. Tropolonebased structures have been identified in over 200 natural compounds, ranging from simple tropolone derivatives to complex multicyclic systems like pycnidione and pyrerubrine A.

These natural compounds exhibit a diverse range of pharmacological effects, including antibacterial, antifungal, insecticidal, phytotoxic, anti-inflammatory, antimitotic, anti-diabetic, enzyme inhibitory, anticancer, cytoprotective, and ROS scavenging properties. It is worth noting that thujaplicane, a compound similar to tropolone, displays all of the listed biological activities except for antimitotic action, which has only been observed in one natural tropolone compound, colchicine.

Tropolone can be synthesized from commercially available seven-membered rings or derived through various cyclization and cycloaddition reactions. Thailandepsin B, on the other hand, can be synthesized by macro-lactonization of the corresponding secoacid, followed by the formation of internal disulfide bonds. It is important to mention that thailandepsin B exhibits different selective inhibition profiles compared to FK228.

Objective: We investigated the HDAC inhibitory activity of the Tropolones and Thailandepsin B and discussed the biosynthesis of the naturally occurring compounds and their synthetic scheme.

Results and Conclusion: It has been observed that Tropolone derivatives act as isoenzyme-selective inhibitors of proven anticancer drug targets, histone deacetylases (HDACs). Some monosubstituted tropolones show remarkable levels of selectivity for HDAC2 and strongly inhibit the growth of T-lymphocyte cell lines. And Thailandepsins have different selective inhibition profiles than FK228. They exhibit comparable inhibitory activities to FK228 against human HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, and HDAC9, but less potent inhibitory activities than FK228 toward HDAC4 and HDAC8, the latter of which may be useful. Thailandepsins possess potent cytotoxic activities toward some types of cell lines.

« Previous Next »
Graphical Abstract

[1]
Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15(12): 3970-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2786] [PMID: 19509171]
[2]
Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 2016; 52(1): 1-11.
[http://dx.doi.org/10.4068/cmj.2016.52.1.1] [PMID: 26865995]
[3]
New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol 2012; 6(6): 637-56.
[http://dx.doi.org/10.1016/j.molonc.2012.09.003] [PMID: 23141799]
[4]
Ononye SN, VanHeyst MD, Oblak EZ, et al. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett 2013; 4(8): 757-61.
[http://dx.doi.org/10.1021/ml400158k] [PMID: 24900743]
[5]
Pauson PL. Tropones and Tropolones. Chem Rev 1955; 55(1): 9-136.
[http://dx.doi.org/10.1021/cr50001a002]
[6]
Ononye SN, VanHeyst MD, Giardina C, Wright DL, Anderson AC. Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells. Bioorg Med Chem 2014; 22(7): 2188-93.
[http://dx.doi.org/10.1016/j.bmc.2014.02.018] [PMID: 24613456]
[7]
Li J, Falcone ER, Holstein SA, Anderson AC, Wright DL, Wiemer AJ. Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis. Pharmacol Res 2016; 113(Pt A): 438-48.
[http://dx.doi.org/10.1016/j.phrs.2016.09.020] [PMID: 27663262]
[8]
Liu N, Song W, Schienebeck CM, Zhang M, Tang W. Synthesis of naturally occurring tropones and tropolones. Tetrahedron 2014; 70(49): 9281-305.
[http://dx.doi.org/10.1016/j.tet.2014.07.065] [PMID: 25400298]
[9]
Zhao J, Zhao J. Plant troponoids: chemistry, biological activity, and biosynthesis. Curr Med Chem 2007; 14(24): 2597-621.
[http://dx.doi.org/10.2174/092986707782023253] [PMID: 17979713]
[10]
Karchesy JJ, Kelsey RG, González-Hernández MP. Yellow-cedar, Callitropsis (Chamaecyparis) nootkatensis, secondary metabolites, biological activities, and chemical ecology. J Chem Ecol 2018; 44(5): 510-24.
[http://dx.doi.org/10.1007/s10886-018-0956-y] [PMID: 29654493]
[11]
Saniewski M, Horbowicz M, Kanlayanarat S. The biological activities of troponoids and their use in agriculture a review. J Hortic Res 2014; 22(1): 5-19.
[http://dx.doi.org/10.2478/johr-2014-0001]
[12]
Keith Michael P, Gilliland William R. Uhl, Kathleen. “GOUT”. Pharmacol Ther 2009; 1039-46.
[13]
Jiang HL, Zhang YY, Mao HY, et al. Strophiofimbrins A and B: Two rearranged norditerpenoids with novel tricyclic carbon skeletons from Strophioblachia fimbricalyx. J Org Chem 88(9): 5936--43.
[http://dx.doi.org/10.1021/acs.joc.3c00301] [PMID: 37043752]
[14]
Moore BS, Walker K, Tornus I, Handa S, Poralla K, Floss HG. Biosynthetic studies of ω-cycloheptyl fatty acids in Alicyclobacillus cycloheptanicus. Formation of cycloheptanecarboxylic acid from phenylacetic acid. J Org Chem 1997; 62(7): 2173-85.
[http://dx.doi.org/10.1021/jo962402o] [PMID: 11671526]
[15]
Hartung EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis 1954; 13(3): 190-200.
[http://dx.doi.org/10.1136/ard.13.3.190] [PMID: 13198053]
[16]
Sheldrake P, Suckling K, Woodhouse R, et al. Biosynthesis. Part 30. 1 Colchicine: studies on the ring expansion step focusing on the fate of the hydrogens at C-4 of autumnaline. J Chem Soc 1998; (18): 3003-10.
[17]
Cox RJ, Al-Fahad A. Chemical mechanisms involved during the biosynthesis of tropolones. Curr Opin Chem Biol 2013; 17(4): 532-6.
[http://dx.doi.org/10.1016/j.cbpa.2013.06.029] [PMID: 23870699]
[18]
Davison J, al Fahad A, Cai M, et al. Genetic, molecular, and biochemical basis of fungal tropolone biosynthesis. Proc Natl Acad Sci USA 2012; 109(20): 7642-7.
[http://dx.doi.org/10.1073/pnas.1201469109] [PMID: 22508998]
[19]
Franck-Neumann M, Brion F, Martina D. Friedel-crafts acylation of tropone-irontricarbonyl. Synthesis of β-thujaplicin and β-dolabrin. Tetrahedron Lett 1978; 19(50): 5033-6.
[http://dx.doi.org/10.1016/S0040-4039(01)85802-0]
[20]
Scott AI, McCapra F, Buchanan RL, Day AC, Young DW. Total synthesis of colchicine modelled on a biogenetic theory. Tetrahedron 1965; 21(12): 3605-31.
[http://dx.doi.org/10.1016/S0040-4020(01)96977-7] [PMID: 5879168]
[21]
Sunagawa G, Nakamura T, Nakazawa J. Studies on the Total Synthesis of dl-Colchiceine. II. Synthesis of dl-Demethoxydeoxyhexahydrocolchiceine. Chem Pharm Bull (Tokyo) 1962; 10(4): 291-9.
[http://dx.doi.org/10.1248/cpb.10.291] [PMID: 13918403]
[22]
Ning C, Wang XC, Pan XF. A practical total synthesis of taxamairin B. Synth Commun 1999; 29(12): 2115-22.
[http://dx.doi.org/10.1080/00397919908086205]
[23]
Banwell MG, Berak M, Hockless DC. Construction of the colchicine framework via two consecutive cyclopropane-mediated ring-expansion reactions. J Chem Soc 1996; (18): 2217-9.
[24]
Zachary Oblak E, Bolstad ESD, Ononye SN, Priestley ND, Kyle Hadden M, Wright DL. The furan route to tropolones: probing the antiproliferative effects of β-thujaplicin analogs. Org Biomol Chem 2012; 10(43): 8597-604.
[http://dx.doi.org/10.1039/c2ob26553b] [PMID: 23032214]
[25]
Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem 2008; 51(6): 1505-29.
[http://dx.doi.org/10.1021/jm7011408] [PMID: 18247554]
[26]
Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459(7243): 55-60.
[http://dx.doi.org/10.1038/nature07925] [PMID: 19424149]
[27]
Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24(19): 8467-76.
[http://dx.doi.org/10.1128/MCB.24.19.8467-8476.2004] [PMID: 15367668]
[28]
Bentley R. A fresh look at natural tropolonoids. Nat Prod Rep 2008; 25(1): 118-38.
[http://dx.doi.org/10.1039/B711474E] [PMID: 18250899]
[29]
Falcone ER. Investigating the antiproliferative activity of synthetic troponoids. University of Connecticut 2016. PhD thesis
[30]
Inamori Y, Shinohara S, Tsujibo H, et al. Antimicrobial activity and metalloprotease inhibition of hinokitiol-related compounds, the constituents of Thujopsis dolabrata S. and Z. hondai MAK. Biol Pharm Bull 1999; 22(9): 990-3.
[http://dx.doi.org/10.1248/bpb.22.990] [PMID: 10513629]
[31]
Mizutani F, Rabbany ABMG, Akiyoshi H. Inhibition of ethylene production and 1-aminocyclopropane-1-carboxylate oxidase activity by tropolones. Phytochemistry 1998; 48(1): 31-4.
[http://dx.doi.org/10.1016/S0031-9422(97)01093-5] [PMID: 9429317]
[32]
Morita H, Matsumoto K, Takeya K, Itokawa H, Iitaka Y. Structures and solid state tautomeric forms of two novel antileukemic tropoloisoquinoline alkaloids, pareirubrines A and B, from Cissampelos pareira. Chem Pharm Bull (Tokyo) 1993; 41(8): 1418-22.
[http://dx.doi.org/10.1248/cpb.41.1418] [PMID: 8403090]
[33]
Seidel C, Schnekenburger M, Dicato M, Diederich M. Histone deacetylase modulators provided by Mother Nature. Genes Nutr 2012; 7(3): 357-67.
[http://dx.doi.org/10.1007/s12263-012-0283-9] [PMID: 22328271]
[34]
Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett 2009; 280(2): 211-21.
[http://dx.doi.org/10.1016/j.canlet.2009.02.013] [PMID: 19289255]
[35]
Bressi JC, Jennings AJ, Skene R, et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett 2010; 20(10): 3142-5.
[http://dx.doi.org/10.1016/j.bmcl.2010.03.091] [PMID: 20392638]
[36]
Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90(1): 85-94.
[http://dx.doi.org/10.1038/icb.2011.100] [PMID: 22124371]
[37]
Jose B, Okamura S, Kato T, Nishino N, Sumida Y, Yoshida M. Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α-tubulin sequence. Bioorg Med Chem 2004; 12(6): 1351-6.
[http://dx.doi.org/10.1016/j.bmc.2004.01.014] [PMID: 15018907]
[38]
Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005; 96(2): 293-304.
[http://dx.doi.org/10.1002/jcb.20532] [PMID: 16088937]
[39]
Lobjois V, Frongia C, Jozan S, Truchet I, Valette A. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 2009; 45(13): 2402-11.
[http://dx.doi.org/10.1016/j.ejca.2009.05.026] [PMID: 19553104]
[40]
Wang C, Henkes LM, Doughty LB, et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod 2011; 74(10): 2031-8.
[http://dx.doi.org/10.1021/np200324x] [PMID: 21793558]
[41]
Depoorter E, Bull MJ, Peeters C, Coenye T, Vandamme P, Mahenthiralingam E. Burkholderia: an update on taxonomy and biotechnological potential as antibiotic producers. Appl Microbiol Biotechnol 2016; 100(12): 5215-29.
[http://dx.doi.org/10.1007/s00253-016-7520-x] [PMID: 27115756]
[42]
Benelkebir H, Donlevy AM, Packham G, Ganesan A. Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor. Org Lett 2011; 13(24): 6334-7.
[http://dx.doi.org/10.1021/ol202197q] [PMID: 22091906]
[43]
Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 2008; 130(6): 1806-7.
[http://dx.doi.org/10.1021/ja7110064] [PMID: 18205365]
[44]
Jung M, Hoffmann K, Brosch G, Loidl P. Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett 1997; 7(13): 1655-8.
[http://dx.doi.org/10.1016/S0960-894X(97)00284-9]
[45]
Brosowsky J, Lutterbeck M, Liebich A, et al. Syntheses of thailandepsin B pseudo-natural products: Access to new highly potent hdac inhibitors via late-stage modification. Chemistry 2020; 26(69): 16241-5.
[http://dx.doi.org/10.1002/chem.202002449] [PMID: 32725698]
[46]
Narita K, Katoh T. Total synthesis of thailandepsin B, a potent HDAC inhibitor isolated from a microorganism. Chem Pharm Bull (Tokyo) 2016; 64(7): 913-7.
[http://dx.doi.org/10.1248/cpb.c16-00060] [PMID: 27373645]
[47]
Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4): 683-92.
[http://dx.doi.org/10.1016/j.cell.2007.01.029] [PMID: 17320506]
[48]
Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs 2009; 69(14): 1911-34.
[http://dx.doi.org/10.2165/11315680-000000000-00000] [PMID: 19747008]
[49]
Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62(17): 4916-21.
[PMID: 12208741]
[50]
Walsh CT, Fischbach MA. Natural products version 2.0: connecting genes to molecules. J Am Chem Soc 2010; 132(8): 2469-93.
[http://dx.doi.org/10.1021/ja909118a] [PMID: 20121095]
[51]
Cheng YQ, Yang M, Matter AM. Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968. Appl Environ Microbiol 2007; 73(11): 3460-9.
[http://dx.doi.org/10.1128/AEM.01751-06] [PMID: 17400765]
[52]
Caboche S, Leclère V, Pupin M, Kucherov G, Jacques P. Diversity of monomers in nonribosomal peptides: Towards the prediction of origin and biological activity. J Bacteriol 2010; 192(19): 5143-50.
[http://dx.doi.org/10.1128/JB.00315-10] [PMID: 20693331]
[53]
Wilson AJ, Cheng YQ, Khabele D. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. J Ovarian Res 2012; 5(1): 12.
[http://dx.doi.org/10.1186/1757-2215-5-12] [PMID: 22531354]
[54]
Wegener D, Hildmann C, Riester D, Schwienhorst A. Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Anal Biochem 2003; 321(2): 202-8.
[http://dx.doi.org/10.1016/S0003-2697(03)00426-3] [PMID: 14511685]
[55]
Narita K, Fukui Y, Sano Y, et al. Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities. Eur J Med Chem 2013; 60: 295-304.
[http://dx.doi.org/10.1016/j.ejmech.2012.12.023] [PMID: 23313638]
[56]
Shiina I. Total synthesis of natural 8- and 9-membered lactones: recent advancements in medium-sized ring formation. Chem Rev 2007; 107(1): 239-73.
[http://dx.doi.org/10.1021/cr050045o] [PMID: 17212476]
[57]
Chen H, Bian Z, Ravichandran V, et al. Biosynthesis of polyketides by trans -AT polyketide synthases in Burkholderiales. Crit Rev Microbiol 2019; 45(2): 162-81.
[http://dx.doi.org/10.1080/1040841X.2018.1514365] [PMID: 31218924]
[58]
Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem 2020; 27(15): 2449-93.
[http://dx.doi.org/10.2174/0929867325666181016163110] [PMID: 30332940]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy